AZ's tozorakimab shows broad COPD benefits ahead of FDA priority review
TL;DR
AZ’s IL-33 inhibitor tozorakimab delivered meaningful reductions in COPD exacerbations in two pivotal trials (Oberon and Titania), cutting moderate/severe attacks by about 29–34% in former smokers and around 30% overall in current/former smokers. Benefits extended across eosinophil subgroups and included a mucus plug score reduction, suggesting broad, differentiated efficacy. The company has secured FDA priority review, positioning tozorakimab as a potential flagship COPD biologic as it competes with other pipeline therapies.
- AZ's R&D chief Barr touts internal 'science success story' after IL-33 antibody's stellar showing in COPD fiercebiotech.com
- AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes CNBC
- AstraZeneca Says Lung-Disease Drug Shows Benefits Across Patient Groups WSJ
- Sanofi spells out asthma data, AstraZeneca details COPD win at #ERS26 Endpoints News
- Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials AstraZeneca
Want the full story? Read the original reporting
Read on fiercebiotech.com